Given the relatively recent approval of semaglutide 2.4 mg and tirzepatide, real-world evidence on the effectiveness of these therapies for chronic weight management is limited
It belongs to the same class of compounds as BPC-157, Sermorelin, and other therapeutic peptides, though it works through an entirely different receptor system
This intervention alleviated abnormalities in iron homeostasis, lipid peroxidation, and antioxidant system damage, inhibited ferroptosis, and improved neurological damage and cognitive dysfunction
Monitoring focuses on liver/kidney context, glucose, lipids, and muscle-stress markers when training load is relevant
These options are often a good fit for patients whose insurance covers weight loss medications